Trial saw 21 people die from the vaccine, 40% more than those in the Placebo group.
The Pfizer Covid-19 vaccine has been reportedly killing people right across the world since its launch earlier this year. Some experts estimate that over 100,000 people have been fatally injured by the jab in the US alone.
When the company completed its trial it proudly announced that the vaccine was 96.7% effective against Covid-19 and didn't mention anything about safety, or the fact that 21 people had died during the trial. This was not a scientific paper they were releasing, this was an advert for their product. But that didn't matter, politicians, the media and health officials all swallowed the sales-pitch whole.
Not long after the vaccine began being given to patients people started dying. Firstly no link was made, then it was denied, followed by being reluctantly acknowledged, before now being known but ignored.
In a recent article in the BMJ, a whistle-blower exposed serious problems she had observed first-hand in the Pfizer vaccine trial in Texas.
A regional director who was employed at the research organisation Ventavia Research Group has told the BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial. Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding. After repeatedly notifying Ventavia of these problems, the regional director, Brook Jackson, emailed a complaint to the US Food and Drug Administration (FDA). Ventavia fired her later the same day. Jackson has provided the BMJ with dozens of internal company documents, photos, audio recordings, and emails.
Now it has emerged that during the last trial Pfizer had 21 people die after receiving the their experimental gene-editing drug, compared to 15 in the placebo group. In real terms that is 40% higher fatality rate than in those who didn't receive the vaccine.
But even more alarming, Pfizer are not continuing to monitor those that they gave the drug to. Meaning that once the trial had ended they ceased being observed. Those patients may well have since died so we have no way of knowing the real death toll from this trial. As one statistician pointed out, "we know that deaths in the BNT162b2 group are at least 40% higher than then that of the placebo, but with no post-marketing data for 6 months, 1 or 3 years we have no-way of knowing the final death-tally"